|
Hemato-oncology / Review
Korean expert consensus on the management of thrombotic thrombocytopenic purpura
Seo-Yeon Ahn, Junshik Hong, Jin Seok Kim, Sung-Hyun Kim, Kyoung Ha Kim, Ho-Young Yhim, Yoo Jin Lee, Jaewoo Song, Soo-Mee Bang, Ji Hyun Lee, Seongsoo Jang, Sung Hwa Bae; on behalf of the Korean Society of Hematology Thrombosis and Hemostasis Working Party and the Korean Society on Thrombosis and Hemostasis
Korean J Intern Med. 2026;41(4):572-584. Published online July 1, 2026
Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening thrombotic microangiopathy resulting from severe ADAMTS13 deficiency. Although effective treatments, such as therapeutic plasma exchange, immunosuppressive therapy with rituximab, and caplacizumab, have significantly improved s..
|
|
|
Hemato-oncology / Original Article
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2024;39(3):501-512. Published online January 30, 2024
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).
Methods: This multicenter prospective cohort study enrolled newly diagnosed pat..
|
|
|
Hemato-oncology / Original Article
Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience
Min-Young Lee, Seug Yun Yoon, Kyoung Ha Kim, Namsu Lee, Ha Youn Kim, Jung Hwa Hwang, Jong-Ho Won
Korean J Intern Med. 2021;36(3):689-698. Published online January 8, 2021
Background/Aims: A better understanding of cancer cell biology has led to the discovery and development of several new targeted agents for cancer. These drugs are widely used in cancer treatment and have good toxicity profiles. However, some patients are extremely sensitive to these drugs and can de..
|
|
|
Hemato-oncology / Original Article
Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
Ho-Young Yhim, Won-Il Choi, Sung-Hyun Kim, Seung-Hyun Nam, Kyoung Ha Kim, Yeung-Chul Mun, Doyeun Oh, Hun-Gyu Hwang, Keun-Wook Lee, Eun-Kee Song, Yong Shik Kwon, Soo-Mee Bang
Korean J Intern Med. 2019;34(5):1125-1135. Published online May 23, 2018
Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients.
Methods: In th..
|
|
|
Hemato-oncology / Original Article
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Young Sok Ji, Min Sung Lee, Chang Wook Min, Seong Kyu Park, Se Hyung Kim, Jina Yun, Hyun Jung Kim, Kyoung Ha Kim, Chan Kyu Kim, Kyu-Taek Lee, Jong-Ho Won, Dae Sik Hong
Korean J Intern Med. 2016;31(4):750-761. Published online March 28, 2016
Background/Aims: There is controversy about the prophylactic effect of anti-thymocyte globulin (ATG) on graft versus host disease (GVHD) in the setting of matched related-donor hematopoietic stem cell transplantation (HSCT). This study assessed the inf luences of ATG on the incidences of acute and c..
|
|
|
